Abstract
New products, that are often more expensive than existing treatments, are launched every year to treat various diseases. Patients, providers, and payers desire better outcomes at lower, controllable and more predictable costs. In this chapter, we demonstrate, using examples, how the value of a new product can be attributed to different factors like improved efficacy, safety and cost-saving. Then we describe the various pharmacoeconomic analyses used to identify and evaluate the value of new therapies. We discuss the various costs that are considered in these analyses (direct, indirect, intangible, and opportunity costs), and different types of analyses that are often utilized (cost of illness, cost-minimization, cost-benefit, cost-effectiveness, and cost-utility analyses) along with examples. Payers and providers may use the results of such analyses to make formulary and coverage decisions. Finally, we discuss steps taken by some states in the US to control drug pricing and reimbursement, and the potential of recently launched biosimilars to lower health care costs spent on biological products.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Argenta C, Ferreira MA, Sander GB, Moreira LB (2011) Short-term therapy with enoxaparin or unfractionated heparin for venous thromboembolism in hospitalized patients: utilization study and cost-minimization analysis. Value Health 14:S89–S92
Arrieta A, Page TF, Veledar E, Nasir K (2017a) Economic evaluation of PCSK9 inhibitors in reducing cardiovascular risk from health system and private payer perspectives. PLoS One 12(1):e0169761
Arrieta A, Hong JC, Khera R, Virani SS, Krumholz HM, Nasir K (2017b) Updated cost-effectiveness assessments of PCSK9 inhibitors from the perspectives of the health system and private payers: insights derived from the FOURIER trial. JAMA Cardiol 2(12):1369–1374
Bootman JL, Townsend JT, McGhan WF (1991) Principles of pharmacoeconomics. Harvey Whitney Books, Cincinnati
Chang K, Nash D (1998) The role of pharmacoeconomic evaluations in disease management. PharmacoEconomics 14(1):11–17
Collins AJ, Li S, Ebben J, Ma JZ, Manning W (2000) Hematocrit levels and associated Medicare expenditures. Am J Kidney Dis 36(2):282–293
Coyle D, Lee K, Laupacis A, Fergusson D (1999) Economic analysis of erythropoietin in surgery. Canadian Coordinating Office for Health Technology Assessment, Ottawa
Goulart B, Ramsey S (2011) A trial-based assessment of the utility of Bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer. Value Health 14:836–845
Grauer DW, Lee J, Odom TD, Osterhaus JT, Sanchez LA (2003) Pharmacoeconomics and outcomes: applications for patient care, 2nd edn. American College of Clinical Pharmacy, Kansas City
Hwang TJ, Kesselheim AS, Sarpatwari A (2017) Value-based pricing and state reform of prescription drug costs. JAMA 318(7):609–610
Joshnson N, Nash D (eds) (1996) The role of pharmacoeconomics in outcomes management. American Hospital Publishing, Chicago
Kazi DS, Moran AE, Coxson PG, Penko J, Ollendorf DA, Pearson SD, Tice JA, Guzman D, Bibbins-Domingo K (2016) Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease. JAMA 316(7):743–753
Kazi DS, Penko J, Coxson PG, Moran AE, Ollendorf DA, Tice JA, Bibbins-Domingo K (2017) Updated cost-effectiveness analysis of PCSK9 inhibitors based on the results of the FOURIER trial. JAMA 318(8):748–750
Sarpatwari A, Avorn J, Kesselheim AS (2016) State initiatives to control medication costs — can transparency legislation help? N Engl J Med 374:2301–2304
Segel JE (2006) Cost-of-illness studies—a primer, RTI-UNC center of excellence in health promotion economics, Jan 2006. http://www.rti.org/pubs/coi_primer.pdf
Szcus TD, Schneeweiss S (2003) Pharmacoeconomics and its role in the growth of the biotechnology industry. J Commer Biotechnol 10(2):111–122
Townsend R (1987) Postmarketing drug research and development. Drug Intell Clin Pharm 21(1pt 2):134–136
Walkom E, Robertson J, Newby D, Pillay T (2006) The role of pharmacoeconomics in formulary decision-making: considerations for hospital and managed care pharmacy and therapeutics committees. Formulary 41:374–386
Suggested Reading
Pharmacoeconomic Methods and Pricing Issues
Bonk RJ (1999) Pharmacoeconomics in perspective. Pharmaceutical Products Press, New York
Drummond MF, O’Brien BJ, Stoddart GL, Torrance GW (1997) Methods for the economic evaluation of health care programmes, 2nd edn. Oxford University Press, Oxford
Kolassa EM (1997) Elements of pharmaceutical pricing. Pharmaceutical Products Press, New York
Pharmacoeconomics of Biotechnology Drugs
Dana WJ, Farthing K (1998) The pharmacoeconomics of high-cost biotechnology products. Pharm Pract Manag Q 18(2):23–31
Hui JW, Yee GC (1998a) Pharmacoeconomics of biotechnology drugs (part 1 of 2). J Am Pharm Assoc 38(1):93–97
Hui JW, Yee GC (1998) Pharmacoeconomics of biotechnology drugs (part 2 of 2). J Am Pharm Assoc 38(2):231–233
Reeder CE (1995) Pharmacoeconomics and health care outcomes management: focus on biotechnology (special supplement). Am J Health Syst Pharm 52:19,S4):S1–19,S4)S28
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Patel, A.S., Shirur, K.P. (2019). Economic Considerations in Medical Biotechnology. In: Crommelin, D., Sindelar, R., Meibohm, B. (eds) Pharmaceutical Biotechnology. Springer, Cham. https://doi.org/10.1007/978-3-030-00710-2_11
Download citation
DOI: https://doi.org/10.1007/978-3-030-00710-2_11
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-00709-6
Online ISBN: 978-3-030-00710-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)